Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Published

Journal Article

Although there is no standard treatment protocol for inflammatory breast cancer (IBC), multi-modality treatment has improved survival. In this study we profiled the NCI approved oncology drug set in a qHTS format to identify those that are efficacious in basal type and ErbB2 overexpressing IBC models. Further, we characterized the sensitivity of an acquired therapeutic resistance model to the oncology drugs. We observed that lapatinib-induced acquired resistance in SUM149 cells led to cross-resistance to other targeted- and chemotherapeutic drugs. Removal of the primary drug to which the model was developed led to re-sensitization to multiple drugs to a degree comparable to the parental cell line; this coincided with the cells regaining the ability to accumulate ROS and reduced expression of anti-apoptotic factors and the antioxidant SOD2. We suggest that our findings provide a unique IBC model system for gaining an understanding of acquired therapeutic resistance and the effect of redox adaptation on anti-cancer drug efficacy.

Full Text

Duke Authors

Cited Authors

  • Williams, KP; Allensworth, JL; Ingram, SM; Smith, GR; Aldrich, AJ; Sexton, JZ; Devi, GR

Published Date

  • August 2013

Published In

Volume / Issue

  • 337 / 1

Start / End Page

  • 77 - 89

PubMed ID

  • 23689139

Pubmed Central ID

  • 23689139

Electronic International Standard Serial Number (EISSN)

  • 1872-7980

International Standard Serial Number (ISSN)

  • 0304-3835

Digital Object Identifier (DOI)

  • 10.1016/j.canlet.2013.05.017

Language

  • eng